Levosulpiride-d_3

Cat. No.: HY-B1059S

CAS No.: 124020-27-5

Molecular Formula: $C_{15}H_{20}D_3N_3O_4S$

Molecular Weight: 344.44

Target: Dopamine Receptor; Isotope-Labeled Compounds

Pathway: GPCR/G Protein; Neuronal Signaling; Others

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (145.16 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.9033 mL	14.5163 mL	29.0326 mL
	5 mM	0.5807 mL	2.9033 mL	5.8065 mL
	10 mM	0.2903 mL	1.4516 mL	2.9033 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Levosulpiride-d_3 is the deuterium labeled Levosulpiride. Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class[1][2].

IC_{50} & Target

D_3 Receptor

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Triebel J, et al. From Bench to Bedside: Translating the Prolactin/Vasoinhibin Axis. Front Endocrinol (Lausanne). 2017;8:342. Published 2017 Dec 11.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA